Month: March 2021

Résultats annuels 2020  Forte amélioration de la rentabilité et atteinte des objectifs 2020Ambitions 2021 et 2023 confirmées et visibilité long terme renforcée Forte progression des résultats en 2020, malgré la crise sanitaire·Croissance des revenus (+33%), de l’EBITDA (+50%) et du résultat net part du Groupe (+71%) Objectifs 2020 atteintsCapacité installée de 1,015 gigawatts (+50%) Capacité sous gestion pour les clients tiers de 2,4 gigawatts (x5 comparé à fin 2019) EBITDA normatif1 de 101,1 millions d’eurosConfirmation des objectifs 2021 et des ambitions 2023Objectif 2021 d’EBITDA normatif2 de 170 millions d’euros Ambitions 2023 d’une capacité en exploitation et en construction, déjà totalement sécurisée, de 2,6 gigawatts, pour un EBITDA normatif2 de 275 à 300 millions d’eurosStructure financière robuste et visibilité long terme...

Full year 2020 results: profitability improves sharply, 2021 objectives achievedand 2023 ambitions confirmed, long-term visibility reinforced Strong increase of 2020 results despite the context of sanitary crisisGrowth of revenues (+33%), of the EBITDA (+50%) and of the net profit, Group share (+71%) 2020 targets achievedInstalled capacity of 1.015 gigawatt (+50%) 2.4 gigawatt-capacity serviced for third party clients (x5 compared with end 2019) Normalised1 EBITDA of €101.1 million2021 target and 2023 ambitions confirmedNormalised2 2021 EBITDA target of €170 million 2023 capacity ambitions in operation and under construction, already fully secured of 2.6 gigawatts, and a Normalised2 EBITDA of €275-300 millionRobust financial structure and long-term visibility reinforced  Contained gearing ratio (55%) and substantial cash...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Switzerland, March 25, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 on the same economic terms as previously proposed to the bondholders’ meeting of March 8, 2021. Santhera announces the publication of an offer (the Exchange Offer) to the holders of its outstanding CHF 60 million 5% Convertible Bonds due 2022 (ISIN: CH0353955195, the 2017/22 Bonds) to exchange all 2017/22 Bonds in circulation. Santhera launches the Exchange Offer following the recent bondholders’ meeting held on March 8, 2021. At that meeting, a large majority of 89% of bonds represented voted in favor of the amendments to the terms of the 2017/22 Bonds proposed...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Schweiz, 25. März 2021 — Santhera Pharmaceuticals (SIX: SANN) gibt ein Umtauschangebot für ihre ausstehende 5%-Wandelanleihe über CHF 60 Millionen mit Fälligkeit 2022 bekannt. Die Bedingungen des Angebots sind wirtschaftlich deckungsgleich mit jenen, die der Anleihensgläubigerversammlung vom 8. März 2021 vorgeschlagen wurden. Santhera gibt die Veröffentlichung eines Angebots (das Angebot) an die Inhaber der ausstehenden CHF 60 Millionen 5%-Wandelanleihe mit Fälligkeit 2022 (ISIN: CH0353955195, die 2017/22 Wandelanleihe) zum Umtausch aller im Umlauf befindlichen 2017/22 Wandelobligationen bekannt. Santhera lanciert das Angebot im Anschluss an die kürzlich abgehaltene Anleihensgläubigerversammlung vom 8. März 2021. An...

The testimony of Fed Chief Powell and Treasury Secretary Yellen gave investors a different perspective, leading to a swift change in market direction. Amongst what was discussed, Powell indicated that the stimulus package amounting to $1.9 trillion will cause an unexpected inflation, though he also said the bank already has a contingency plan if they are needed. Here’s an overview of market movements: • Dow Jones Industrial Average lost 308.05 points or 0.94% closing at 32,423• NASDAQ Composite Index tripped down by 149.85 points or 1.12% closing with 13,228• S&P 500 Index slid down by 30.07 points or 0.76% ending at 3,911• Gold upped by 0.19% at 1,728.40• Silver tumbled down by 0.23% at 25.17• Crude Oil gained 1.07% to close with 58.38 NASDAQ, which lost the most out of the e major indexes, was heavily affected by Chief Powell’s...

RockItCoin is pleased to announce they offer Bitcoin ATMs that make the buying and selling process simple and convenient. These ATMs can be found in numerous locations, providing individuals with an easy way to buy, sell and trade Bitcoins and other forms of cryptocurrency. With locations throughout the United States, the Bitcoin ATMs operated by RockItcoin use a special digital wallet account that allows individuals to buy and sell their Bitcoins and other types of cryptocurrency from a convenient ATM, rather than trying to find a broker to use. These ATMs tap into the user’s digital wallet to make transactions from any of its locations. While Bitcoin ATMs are operated by RockItCoin, these ATMs can be requested by any business location, providing their customers with the convenience of buying, selling and trading Bitcoins, using either...

CoinDogg is on a mission to support independent creators by creating a platform that allows them to monetize content on any platform in any currency while rewarding fans for their loyalty with tradable NFTs. If you are new to the world of cryptocurrencies or have simply just not yet been introduced to NFTs, sit back, relax and let’s take you on a journey exploring the hottest topic in crypto of 2021. Non-Fungible Tokens Explained Non-Fungible Tokens (NFTs) are unique digital assets on the blockchain and can be used to represent ownership of both tangible and intangible items. Most Non-Fungible Tokens have been created on Ethereum, where they used the ERC-721 Standard. Increasingly, however, developers have been looking at other blockchains for NFTs as they look for the most suitable protocol for a growing number of use cases including...

Good morning, Please find below the press release issued today. Best regards,Marishka MartinsGroup PR Consultant  | Group Marketing & Communications Capgemini Group | MumbaiTel.: +91 9930835325Email: marishka.martins@capgemini.com_____________________________  World Retail Banking Report 2021: To create new value, banks can adopt Banking-as-a-Service to embed finance in consumer lifestyles    The post-COVID-19 era will be defined by fierce competition, pushing banks to review priorities and realign investments in growth areas to meet higher customer expectations Paris, March 25, 2021 — Retail banks are facing a choice between aligning their offerings to customer expectations or running the risk of losing those customers altogether, says the World Retail Banking Report 2021 (WRBR) published today by Capgemini and Efma. As...

Bonjour, Vous trouverez ci-après le communiqué de presse diffusé ce jour. Bien cordialement, Florence LièvreGlobal PR Manager | Group Marketing & Communications Capgemini Group | ParisTel.: +33 1 47 54 50 71Email : florence.lievre@capgemini.com_____________________ World Retail Banking Report 2021 : en adoptant une approche « Banking-as-a-Service », les banques peuvent créer de la valeur et intégrer la finance dans le quotidien de leurs clients. L’ère post Covid-19 sera marquée par une concurrence accrue qui obligera les banques à revoir leurs priorités et à réorienter leurs investissements pour répondre aux attentes plus élevées de leurs clients. Paris, le 25 mars 2021 – Selon le World Retail Banking Report 2021 (WRBR) publié aujourd’hui par Capgemini et l’Efma, les banques de détail sont confrontées à un dilemme : aligner...

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome, or ARDS. To be enrolled in the trial, subjects must have been admitted to the hospital with confirmed COVID-19 disease and either require non-invasive mechanical ventilation or have insufficient blood oxygen saturation while on high flow oxygen administration....